Compare Kaltura Inc (KLTR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Neurocrine Biosciences Inc — how do they compare? Kaltura Inc trades at $1.35 (market cap $208.27M), while Neurocrine Biosciences Inc trades at $178.87 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 83.5× Kaltura Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| KLTR | NBIX | |
|---|---|---|
Market Cap | $208.27M | $17.40B |
Sector | Technology | Health |
52-Week High | $1.97 | $180.55 |
52-Week Low | $1.08 | $123.10 |
Enterprise Value | $190.99M | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.385, down 0.36% with a bullish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and revenue stabilizing around $180M. Recent industry recognition includes being named a Leader in virtual event platforms by Forrester and Aragon Research in June 2026. Operating cash flow turned positive in Q1 2026 for the first time in company history, though net margins remain negative at -8.25%.
While technical indicators suggest near-term strength, fundamental challenges persist with negative ROE of -107.84% and high P/B ratio of 44.85. Analyst consensus leans bullish with 44% buy ratings, but profitability concerns and competitive pressures in the digital experience platform space warrant caution. The upcoming Q2 2026 earnings on August 5 will be critical for validating the company's turnaround trajectory.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
